OmicsAI Builds 'Physical AI' Self-Driving Lab to Target Asian Multi-Omics Data Market

OmicsAI, an artificial intelligence (AI)-based multi-omics analysis platform company, has built a 'Physical AI'-based Self-Driving Laboratory and is moving to expand its bio data platform business.

The company plans to improve analysis efficiency through automation systems, while also accelerating its entry into the global new drug development market by building a database (DB) of Asian cancer patients.

On the 28th, OmicsAI announced the opening ceremony of its Self-Driving Laboratory, which automates the entire process—from sample intake to preprocessing, proteomics analysis, and data interpretation—minimizing human intervention.

This facility enhances both the speed and reproducibility of proteomics analysis, establishing a foundation for the stable production and management of large-scale, high-quality data. Through this, the company expects to further strengthen its competitiveness in the field of automated analysis technology.

The opening ceremony was attended by key executives from Agilent Technologies, a global leader in analytical instruments and automated laboratory solutions, including Jonah Kirkwood, Global Senior Vice President (SVP) and Chief Commercial Officer (CCO), and Bharat Bhardwaj, Vice President for Asia-Pacific (APAC). Industry insiders interpret the visit of these core executives from a global analytical instrument firm as a strong endorsement of OmicsAI's automation technology and business potential.

The company expects that the establishment of the Self-Driving Laboratory will enhance both profitability and data competitiveness. By automating the analysis process, OmicsAI aims to reduce costs and boost operational efficiency, while also building a virtuous cycle where the high-quality multi-omics data accumulated during analysis services is leveraged for AI learning.

OmicsAI described this as a 'Data Flywheel' structure. As revenue from analysis services increases, more data is accumulated; this accumulated data then improves AI analysis performance, thereby further strengthening the competitiveness of its services. The company expects that securing cost competitiveness will accelerate this virtuous cycle even more.

OmicsAI is also ramping up collaboration in the field of new drug development. The company is working with Oncocross, a KOSDAQ-listed AI drug development company, to build a multi-omics database of Asian cancer patients. The strategy focuses on the rapidly growing demand for proteomics data reflecting Asian characteristics, amid a global market that has thus far been centered on Western data.

The two companies plan to jointly pursue the construction of the database and analysis service business, while also expanding data-related business and technology out-licensing (L/O) opportunities targeting global pharmaceutical firms.

Jongbae Park, Chief Technology Officer (CTO) at OmicsAI, said, "The Asian cancer patient multi-omics database that we are building with Oncocross based on the Self-Driving Laboratory represents a high-value-added data asset that has never existed before. Our goal is to make this a core data infrastructure that global pharmaceutical companies must utilize when conducting new drug research targeting Asian populations."

Dongmyeong Shin, CEO of OmicsAI, stated, "The establishment of the Self-Driving Laboratory marks a critical turning point, allowing us to move beyond a simple analysis services firm and position ourselves as a data platform company that improves the success rate of drug development and precision medicine. By cooperating with both domestic and global partners, including Oncocross, we aim to build a leading multi-omics data ecosystem representing Asia."

This Self-Driving Laboratory is expected to provide a foundation for OmicsAI to become a data platform company targeting the global new drug development market, leveraging its automated analysis technology and AI-based data competitiveness.

This content was produced with the assistance of AI translation services.